Browsing: Wellness Tips

NEW YORK, July 22 (Reuters) – Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government’s Medicare health insurance program for Americans aged 65 and older, according to early indications from doctors and ‌analysts

It’s been about a year since Patrick Gilligan took the helm of Point32Health, the state’s second-largest health insurer and parent company of Harvard Pilgrim Health Care and Tufts Health Plan

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results

Dr. Alex Tatem, a board-certified urologist in Indiana, discusses why upcoming federal hearings on seven peptides were mandated and argues that years of patient use show a promising safety profile

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks

The weight loss drugs available to Kalamazoo County employees may be life changing, but the county’s cost has ballooned to an unsustainable amount, according to some county leaders

[Sportschosun Reporter Jang Jong-ho] A large population-based study has found that semaglutide, widely used to treat diabetes and obesity, may significantly reduce the risk of adult-onset seizures

According to experts’ estimates, around 350,000 people in Malaga are obese and a further 700,000 are overweight. Obesity is linked to more than …220 health conditions, including those related to cardiovascular and cerebrovascular events. However, the scales are no longer the only factor to consider in the battle against excess weight and, above all, cardiovascular…

New research published in Radiology details the impact of yo-yo dieting on muscle health, highlighting the role of imaging in assessing the broader effects of weight fluctuations. 

Amgen stock sits at the intersection of mature biologic franchises and a broad late-stage pipeline that is increasingly focused on oncology and cardiometabolic diseases. The California-based biotechnology group Amgen Inc. (ISIN US0311621009) combines steady cash generation from legacy drugs such as Enbrel and Prolia with new assets in cancer and obesity, giving investors a blend…